Precision Cancer Medicine Program
At UCSF, we believe that cancer therapy works best when it's tailored to the patient. Our Pediatric Precision Cancer Medicine Program makes this personalized care possible for children, teens and young adults with any kind of cancer, including those whose cancers are rare, high-risk or resistant to standard therapies.
Our team uses cutting-edge tools, such as the UCSF500 Cancer Gene Panel, to identify the genetic signatures of a patient's disease. These findings can help us diagnose cancers more precisely. They also allow us to design novel, personalized treatment plans, with the goal of making therapies work better while also causing fewer side effects. Precision oncologists work alongside other UCSF specialists to ensure that all patients receive high-quality care that's effective and compassionate.
UCSF patients also benefit from our commitment to cancer research. We're the only hospital in Northern California that's a member of the National Cancer Institute's Children's Oncology Group Phase 1/Pilot Consortium – a small group of leading institutions tasked with developing new therapies for pediatric cancers. Many of our physicians are leaders in national research groups dedicated to pediatric cancers, including leukemia, neuroblastoma and pediatric brain tumors. Patients in our Precision Cancer Medicine Program have access to new treatments that are not widely available or that are still being tested in clinical trials.
Many of the precision cancer services we provide are not readily available at other hospitals, and some are offered only at UCSF. But patients who don't live near the Bay Area can still benefit from our expertise: We work with oncologists throughout the United States and world to test tumor samples and guide treatments that can be administered by the patient's local care team.
To schedule an appointment with the Pediatric Precision Cancer Medicine Program, please give us a call at (415) 476-3831.
Please note that many insurance plans require a referral from your child's primary care physician before you schedule a visit at UCSF. We ask that you contact your insurance carrier to check if you need an authorization before your appointment. If a referral is required, please ask your child's primary care physician to fax a referral form and any applicable medical records to the UCSF Pediatric Access Center at (415) 353-4485.
Our locations (1)
MD, MPHPediatric neuro-oncologist
Robert E. Goldsby
Mignon L. Loh
MDPediatric neurologist and neuro-oncologist
Amit J. Sabnis
MD, MSPediatric hematologist-oncologist
Awards & recognition
Best in Northern California for cancer care
Ranked among the nation's best in 10 specialties
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
New visitor rules
Before you head to the hospital, check our special COVID-19 rules for visitors. Thanks!
Related clinics (4)
Blood & Marrow Transplant (BMT) Clinic
General Surgery Clinic
Orthopedic Surgical Oncology Clinic
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philad...
Will compare the DFS of standard risk Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more ...
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With...
MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD ne...
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chr...
The RP2D is the maximum tolerated dose (MTD) or less.
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Dia...
Will be assessed in SR-High patients and SR-Avg B-ALL patients who are negative for MRD by flow cytometry but have detectable or indeterminate MRD as measured by high throughput sequencing (HTS) at end of induction (EOI), and pati...
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Power calculations are based on detecting an improvement in post consolidation DFS with the addition of InO to standard therapy for high risk (HR) B-acute lymphoblastic leukemia (ALL). All survival time analyses assume a Weibull d...
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
Our research initiatives
UCSF Children's Cancer Program Clinical Trials